Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue (2020 - 2021)
Cullinan Therapeutics' (CGEM) quarterly Non-Current Deffered Revenue came in at $65000.0 in Q4 2021, down 12.16% year-on-year from $74000.0 in Q4 2020, and down 2.99% quarter-over-quarter from $67000.0 in Q3 2021.
Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue (2020 - 2021) Analysis & Trends
Cullinan Therapeutics' Non-Current Deffered Revenue history runs 2 years deep, the most recent figure standing at $65000.0 for Q4 2021.
- On a quarterly basis, Non-Current Deffered Revenue fell 12.16% year-over-year to $65000.0 in Q4 2021; TTM through Dec 2021 was $65000.0, a 12.16% decrease from a year earlier, with the FY2021 full-year figure at $65000.0, down 12.16% from the prior year.
- Non-Current Deffered Revenue retreated to $65000.0 in Q4 2021 per CGEM's latest filing, from $67000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $74000.0 in Q4 2020 and bottomed at $65000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cullinan Therapeutics | 368.65 Mn | 368.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 65,000.00 |
| Sep 30, 2021 | 67,000.00 |
| Jun 30, 2021 | 70,000.00 |
| Mar 31, 2021 | 73,000.00 |
| Dec 31, 2020 | 74,000.00 |